Filing Details

Accession Number:
0000899243-18-013571
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-21 16:34:24
Reporting Period:
2018-05-17
Accepted Time:
2018-05-21 16:34:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1377121 Protagonist Therapeutics Inc PTGX Pharmaceutical Preparations (2834) 980505495
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1619859 L.p. X Canaan 285 Riverside Avenue, Suite 250
Westport CT 06880
No No Yes No
1673228 Canaan Partners X Llc 285 Riverside Avenue, Suite 250
Westport CT 06880
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-05-17 38,968 $6.09 2,116,552 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 - $6.46, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.